Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time

Dong, Yue; Nuttall, Gregory A.; Oliver, William C.; Agarwal, Shvetank; Ereth, Mark H.

doi:10.1016/j.jclinane.2007.03.003

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is great uncertainty if any one device is superior when using aprotinin on CPB. Several studies from around the time when aprotinin was withdrawn suggest that the Sonoclot produces more consistent results than the Hemochron Kaolin ACT and is less affected by the drug [29].…”

Section: Future Outlookmentioning

confidence: 99%

ACT 2018 – Lessons to be learned from the past

Falter¹,

Kemna²

2019

Intergr Clin Med

View full text Add to dashboard Cite

In this review we summarize the current status of knowledge and outline future directions regarding the use of activated clotting time devices (ACT) for heparin monitoring.It is over 50 years ago that Paul Hattersley first described the ACT and 40 years ago it was first used as a simple method of heparin management during extracorporeal circulation. Today, ACT is the primary test for monitoring heparin activity in cardiac and vascular operating rooms, intensive care and hemodialysis units as well as in the catheter lab. Without appropriate anticoagulation clot will start to form during these procedures, with a high chance of a fatal event occurring. Currently, there are several POC methods available for ACT measurement, however results obtained with different devices can vary substantially. Furthermore, the target ACTs which are described in guidelines are mostly empiric or based on small-scale studies done with one or different POC ACT devices. Moreover, it is important to realize that there is no "gold standard" ACT method and therefore no "true" ACT. The ACT has gone unchallenged for a long time. Being mostly 'clinician owned' we have come to accept that, in the absence of a gold standard, there is no way to determine if any one of the commercially available devices measures a true ACT value. The lesson to be learned from the last 40 years is that clinicians', laboratory staff 's and manufacturers' approach to the ACT needs to become more collaborative, open and truly multidisciplinary in order to stand up to the level of scrutiny that is increasingly demanded in modern healthcare.

show abstract

Section: Future Outlookmentioning

confidence: 99%